Acurx Pharmaceuticals Inc(ACXP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.05 | Insider Own | 8.12% | Shs Outstand | 5.6M | Perf Week | 3.18% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 12.79% | Insider Trans | - | Shs Float | 5.1M | Perf Month | -16.54% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.38 | Inst Own | 2.15% | Short Float | 2.19% | Perf Quarter | -20.63% |
| Income | -0.01B | P/S | - | EPS this Y | 67.67% | Inst Trans | 3.75% | Short Ratio | 0.92 | Perf Half Y | -42.68% |
| Sales | 0.00B | P/B | 0.65 | EPS next 5Y | 31.04% | ROA | -87.57% | Short Interest | 0.11M | Perf YTD | -54.42% |
| Book/sh | 1.74 | P/C | 0.59 | EPS past 3/5Y | 38.05% 10.54% | ROE | -128.11% | 52W High | -84.95% ($7.54) | Perf Year | -82.54% |
| Cash/sh | 1.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -92.08% | 52W Low | 6.19% ($1.07) | Perf 3Y | -98.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.66% | Gross Margin | - | Volatility(W/M) | 4.03% 5% | Perf 5Y | -98.82% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.88 | EPS Q/Q | 71.96% | Profit Margin | - | RSI (14) | 33.53 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.88 | Sales Q/Q | - | SMA20 | -7.27% ($1.22) | Beta | -2.1 | Target Price | $17 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | -15.16% ($1.33) | Rel Volume | 0.18 | Prev Close | $1.14 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -40.7% - | SMA200 | -43.8% ($2.01) | Avg Volume(3M) | 0.12M | Price | $1.13 |
| IPO | 2021/6/25 | Option/Short | No/Yes | Trades | 130 | Volume | 22,156 | Change | -0.44% |
💊 Acurx Pharmaceuticals () is a late-stage clinical biopharmaceutical company developing a novel class of antibiotics platform (GPSS®) that selectively inhibits Gram-positive DNA polymerase IIIC (pol IIIC). Its lead candidate, ibezapolstat, achieved approximately 94% cure rates in a Phase 2b trial for C. difficile infection (CDI), demonstrating superiority over vancomycin, and is a small-cap stock with a focused antibiotic pipeline preparing to advance into Phase 3.
Over the past 1 year, on the lower side
85% below its 1-year high.
Traded less than usual. That is 18% of its average volume.
ACXP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #532 of 595 in the industry
Based on market cap of $6M.
LEXX#530 Lexaria Bioscience Corp $6M PER - 
FBLG#531 FibroBiologics Inc $6M PER - ACXP#532 Acurx Pharmaceuticals Inc $6M PER - 
ENVB#533 Enveric Biosciences Inc $6M PER - 
AIM#534 AIM ImmunoTech Inc $6M PER - 
FAQ
What kind of company is ACXP?
ACXP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACXP?
The market cap of ACXP is approximately $6M, ranking 5,564 within its sector.
What is the 52-week high and low for ACXP?
ACXP has recorded a 52-week high of $7.54 and a low of $1.07.
